Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Combined with S-1 and Raltitrexed in Refractory mCRC
NCT06427005Phase 2Recruiting
- Start
- Feb 2023
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC). Started Feb 2023; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06427005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427005.